Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Resected pancreatic cancer: landmark ctDNA positivity was associated with earlier recurrence

An ASCO 2025 interim analysis of 112 patients with resected stage I to III pancreatic adenocarcinoma reported that landmark postoperative ctDNA positivity predicted recurrence (HR 2.39; 95% CI 1.14 to 5.01), and longitudinal positivity was associated with shorter disease-free survival (HR 3.13).

Journal of Clinical Oncology